Aligos Therapeutics, Inc. — Form 10-Q
Filed August 6, 2026 · analyzed by the Periodic Agent
10-Q
— Neutral
significance 28/100
What the filing says
Aligos Therapeutics licensed its hepatitis B capsid assembly modulator (pevifoscorvir sodium/ALG-000184) exclusively to Xiamen Amoytop Biotech for development and commercialization in mainland China, Taiwan, Hong Kong, and Macau. Amoytop pays $25 million upfront within [redacted] days, plus regulatory milestones (amounts redacted), sales milestones (tiered structure redacted), and tiered royalties on Net Sales [rates redacted]. Amoytop bears all development, manufacturing, and commercialization costs and must meet specific regulatory milestones. The agreement includes technology transfer support from Aligos, joint governance committees, extensive manufacturing quality controls, data-sharing obligations, and comprehensive IP prosecution rights. Term runs through expiration of all royalty terms in the territory (10 years post-launch or patent/exclusivity expiration, whichever is latest).
Why this rating
Large upfront ($25M ≈ 125% of $19.9M market cap) and potential milestones are material for tiny company. However, heavily redacted milestones/royalty rates obscure true economic value. Agreement is significant deal size but is standard biotech licensing; execution risk remains with Amoytop in China regulatory environment.
See more from August 6, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.